NR4A3 and diffuse large B-cell lymphoma: NOR1 may also be a predictor of outcome in patients with diffuse large B-cell lymphoma (DLBCL): Researchers have observed a moderate increase in NOR1 levels in DLBCL patients who respond very well to chemotherapy, whereas a similar increase has been observed in patients who do not respond to chemotherapy (Shipp et al., 2002).